文献速递肝病

桥接纤维化与肝硬化中预测疾病进展和临床结局的肝硬度阈值

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
PubMed 文献 · Gut · 2022-09-09

本研究利用四项selonsertib和simtuzumab随机安慰剂对照试验的数据,在活检证实的F3-F4期非酒精性脂肪性肝炎(NASH)患者中,确定振动控制瞬时弹性成像(VCTE)肝硬度(LS)预测桥接纤维化进展为肝硬化和肝硬化患者发生肝脏相关事件的阈值。桥接纤维化患者进展为肝硬化的最佳基线LS阈值为≥16.6 kPa,肝硬化患者预测肝脏相关事件的最佳基线LS阈值为≥30.7 kPa。

要点

  • 桥接纤维化患者基线LS≥16.6 kPa预测进展为肝硬化(校正HR 3.99)。
  • LS较基线增加≥5 kPa(且≥20%)独立预测桥接纤维化进展为肝硬化(校正HR 1.98)。
  • 肝硬化患者基线LS≥30.7 kPa预测肝脏相关事件(校正HR 10.13)。

核心结论

  • 本研究所确定的LS阈值可能有助于对晚期纤维化NASH患者进行风险分层。

研究设计与样本

  • 研究使用了四项selonsertib和simtuzumab随机安慰剂对照试验的数据,受试者为晚期纤维化(F3-F4)患者;这些试验因缺乏疗效而终止。
  • 基线及第48周(selonsertib研究)或第96周(simtuzumab研究)集中进行肝纤维化分期。
  • 采用Cox比例风险回归分析确定VCTE测定的LS与疾病进展之间的关联。

主要发现

  • 桥接纤维化患者中16%(103/664)进展为肝硬化,基线肝硬化患者中4%(27/734)发生经裁定的肝脏相关事件。
  • 预测进展为肝硬化的最佳基线LS阈值为≥16.6 kPa,预测肝脏相关事件的最佳基线LS阈值为≥30.7 kPa。
  • 桥接纤维化患者中,基线LS≥16.6 kPa(校正HR 3.99;95% CI 2.66至5.98,p<0.0001)和LS增加≥5 kPa(且≥20%)(校正HR 1.98;95% CI 1.20至3.26,p=0.008)是进展为肝硬化的独立预测因素。
  • 肝硬化患者中,基线LS≥30.7 kPa(校正HR 10.13,95% CI 4.38至23.41,p<0.0001)预测肝脏相关事件。

关键数值与推荐

  • 桥接纤维化患者预测进展为肝硬化的基线LS阈值为≥16.6 kPa。
  • 肝硬化患者预测肝脏相关事件的基线LS阈值为≥30.7 kPa。
  • 桥接纤维化患者中,基线LS≥16.6 kPa的校正HR为3.99(95% CI 2.66至5.98,p<0.0001)。
  • 桥接纤维化患者中,LS增加≥5 kPa(且≥20%)的校正HR为1.98(95% CI 1.20至3.26,p=0.008)。
  • 肝硬化患者中,基线LS≥30.7 kPa的校正HR为10.13(95% CI 4.38至23.41,p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In retrospective studies, liver stiffness (LS) by vibration-controlled transient elastography (VCTE) is associated with the risk of liver decompensation in patients with non-alcoholic steatohepatitis (NASH), but prospective data in biopsy-confirmed cohorts with advanced fibrosis are limited. We aimed to establish thresholds for LS by VCTE that predict progression to cirrhosis among patients with bridging fibrosis and hepatic decompensation among patients with cirrhosis due to NASH. DESIGN: We used data from four randomised placebo-controlled trials of selonsertib and simtuzumab in participants with advanced fibrosis (F3-F4). The trials were discontinued due to lack of efficacy. Liver fibrosis was staged centrally at baseline and week 48 (selonsertib study) or week 96 (simtuzumab study). Associations between LS by VCTE with disease progression were determined using Cox proportional hazards regression analysis. RESULTS: Progression to cirrhosis occurred in 16% (103/664) of participants with bridging fibrosis and adjudicated liver-related events occurred in 4% (27/734) of participants with baseline cirrhosis. The optimal baseline LS thresholds were ≥16.6 kPa for predicting progression to cirrhosis, and ≥30.7 kPa for predicting liver-related events. Baseline LS ≥16.6 kPa (adjusted HR 3.99; 95% CI 2.66 to 5.98, p<0.0001) and a ≥5 kPa (and ≥20%) increase (adjusted HR 1.98; 95% CI 1.20 to 3.26, p=0.008) were independent predictors of progression to cirrhosis in participants with bridging fibrosis, while baseline LS ≥30.7 kPa (adjusted HR 10.13, 95% CI 4.38 to 23.41, p<0.0001) predicted liver-related events in participants with cirrhosis. CONCLUSION: The LS thresholds identified in this study may be useful for risk stratification of NASH patients with advanced fibrosis.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Loomba R, Huang DQ, Sanyal AJ, et al. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut. 2022. PMID: 36750244. doi:10.1136/gutjnl-2022-327777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。